Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

Abstract

RAS -pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS -pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF across three international centers and evaluated their significance. N/KRAS variants were present in 6% of patients and were typically sub-clonal (median VAF\u2009=\u200920%) relative to other genes variants. RAS variants were associated with advanced MF features including leukocytosis ( p \u2009=\u20090.02), high somatic mutation burden ( p \u2009<\u20090.01) and the presence of established “molecular high-risk” (MHR) mutations. MF patients with N/KRAS mutations had shorter 3-year overall survival (OS) (34% vs 58%, p \u2009<\u20090.001) and higher incidence of acute myeloid leukemia at 3 years (18% vs 11%, p \u2009=\u20090.03). In a multivariate Cox model, RAS mutations were associated with decreased OS (HR 1.93, p \u2009<\u20090.001). We created a novel score to predict OS incorporating RAS mutations, and it predicted OS across training and validation cohorts. Patients with intermediate risk/high-risk DIPSS with RAS mutations who received ruxolitinib had a nonsignificant longer 2-year OS relative to those who did not receive ruxolitinib. These data demonstrate the importance of identifying RAS mutations in MF patients.